Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401178 | 0.87 | CACNA1B (0.53) | CACNA1BCNR2NR1I2GAANPC1 | |
| SCHEMBL8153141 | 0.78 | CACNA1B (0.77) | CACNA1BCNR2CNR1NR1I2GAA | |
| SCHEMBL8155243 | 0.78 | CACNA1B (0.50) | CACNA1BCNR2NR1I2GAANPC1 | |
| SCHEMBL13435714 | 0.76 | CACNA1B (0.47) | CACNA1BCNR2CNR1NR1I2GAA | |
| SCHEMBL8151080 | 0.67 | NR1I2 (0.56) | CACNA1BNR1I2GAANPC1ALDH1A1 | |
| SCHEMBL8144031 | 0.67 | NR1I2 (0.67) | CACNA1BCNR2NR1I2GAANPC1 | |
| SCHEMBL8150541 | 0.67 | CACNA1B (0.69) | CACNA1BNR1I2ALDH1A1 | |
| SCHEMBL8156552 | 0.66 | CACNA1B (1.00) | CACNA1BNR1I2GAANPC1ALDH1A1 | |
| SCHEMBL8157437 | 0.66 | CACNA1B (0.84) | CACNA1BNR1I2GAANPC1ALDH1A1 | |
| SCHEMBL8150100 | 0.66 | NR1I2 (0.61) | CACNA1BCNR2NR1I2GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | CACNA1B 13/4885CNR2 66/4885CNR1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.